Abstract: Cervical cancer is one of the most common malignancies in women, ranking the second in the incidence of malignancy in Asia, second only to breast cancer, and the mortality rate is at 4th place. At present, concurrent radiotherapy and chemotherapy is a standard treatment program for advanced cervical cancer, which can provide the effective rate of treatment and the survival rate of patients, adverse reactions can be tolerated, but the combined use of concurrent chemotherapy regimens, benefit groups and targeted drugs remains to be further studied. Radiotherapy can be combined at different times with different types of chemotherapeutic agents, to improve the therapeutic effect. Related studies have shown that cisplatin and nedaplatin monotherapy treatment has the quite effect compared with platinum combined with fluorouracil, tegafur and other drugs 21 days of the program, but the monotherapy treatment has the smaller toxic side effects. Paclitaxel and nedaplatin are effective in consolidating chemotherapy regimens. Cisplatin-containing concurrent radiochemotherapy is recommended as the preferred treatment of locally advanced cervical cancer.

Key words: Uterine cervical neoplasms, Neoplasms, squamous cell, Antineoplastic combined chemotherapy protocols, Radiotherapy